Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study

Annals of the Rheumatic Diseases

Volumn 76, Issue 6, 2017, Pages 1070-1077

  Braun, Jürgen ^a   Baraliakos, Xenofon ^a   Deodhar, Atul ^b   Baeten, Dominique ^c   Sieper, Joachim ^d   Emery, Paul ^e   Readie, Aimee ^f   Martin, Ruvie ^f   Mpofu, Shephard ^f   Richards, Hanno B ^f  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; GLUCOCORTICOID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE; SECUKINUMAB; TUMOR NECROSIS FACTOR ANTIBODY; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ANKYLOSING SPONDYLITIS; ARTHRALGIA; ARTICLE; BACKACHE; BRAIN ISCHEMIA; CANDIDIASIS; CLINICAL FEATURE; CLINICAL OUTCOME; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; GENITAL CANDIDIASIS; HEADACHE; HEART INFARCTION; HUMAN; INFLUENZA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MEDICAL SOCIETY; MODIFIED STOKE ANKYLOSING SPONDYLITIS SPINE SCORE; NAUSEA; NEUTROPENIA; OROPHARYNX PAIN; OUTCOME ASSESSMENT; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SKIN CANDIDIASIS; SPINE RADIOGRAPHY; SYMPTOM; THRUSH; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; UVEITIS; X RAY; CHEMICALLY INDUCED; CLINICAL TRIAL; CROHN DISEASE; DIAGNOSTIC IMAGING; MIDDLE AGED; RADIOGRAPHY; SPONDYLITIS, ANKYLOSING; SYMPTOM ASSESSMENT;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; CANDIDIASIS; CROHN DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; PSORIASIS; RADIOGRAPHY; SPONDYLITIS, ANKYLOSING; SYMPTOM ASSESSMENT; UVEITIS;

EID: 85006986273     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-209730     Document Type: Article

References (49)

1. Ghasemi-Rad M, Attaya H, Lesha E, et al. Ankylosing spondylitis: a state of the art factual backbone. World J Radiol 2015;7:236-52.
2. Dougados M, Baeten D. Spondyloarthritis. Lancet 2011;377:2127-37.
3. Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009;68(SUPPL. 2):ii1-44.
4. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904.
5. Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol 2016;68:282-98.
6. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46.
7. Davis JC Jr, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
8. Inman RD, Davis JC Jr, van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008;58:3402-12.
9. van der Heijde D, Dijkmans B, Geusens P, et al., Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52: 582-91.
10. Landewé R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 2014;73:39-47.
11. Braun J, Kiltz U, Heldmann F, et al. Emerging drugs for the treatment of axial and peripheral spondyloarthritis. Expert Opin Emerg Drugs 2015;20:1-14.
12. Baraliakos X, Listing J, Fritz C, et al. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years-early clinical response predicts long-term outcome. Rheumatology (Oxford) 2011;50:1690-9.
13. Braun J, Baraliakos X, Hermann KG, et al. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Ann Rheum Dis 2014;73:1107-13.
14. van der Heijde D, Salonen D, Weissman BN, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009;11:R127.
15. van der Heijde D, Landewé R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008;58:3063-70.
16. van der Heijde D, Landewé R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58:1324-31.
17. Appel H, Maier R, Wu P, et al. Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 2011;13:R95.
18. Bowness P, Ridley A, Shaw J. Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol 2011;186:2672-80.
19. DeLay ML, Turner MJ, Klenk EI, et al. HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum 2009;60:2633-43.
20. Glatigny S, Fert I, Blaton MA, et al. Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats. Arthritis Rheum 2012;64:110-20.
21. Kenna TJ, Davidson SI, Duan R, et al. Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive y/8 T cells in patients with active ankylosing spondylitis. Arthritis Rheum 2012;64:1420-9.
22. Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum 2012;64:99-109.
23. Sarin R, Wu X, Abraham C. Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses. Proc Natl Acad Sci USA 2011;108:9560-5.
24. Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 2009;60:1647-56.
25. Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-yt+ CD3+CD4-CD8-entheseal resident T cells. Nat Med 2012;18:1069-76.
26. van Tok M, van Duivenvoorde L, Kramer I, et al. Anti-IL-17A treatment blocks inflammation, destruction and new bone formation in experimental spondyloarthritis in HLA-B27 transgenic rats [abstract]. Arthritis Rheumatol 2015;67(Suppl 10). http://acrabstracts.org/abstract/anti-il-17a-treatment-blocks-inflammation-destruction-and-new-bone-formation-in-experimental-spondyloarthritis-in-hla-b27-transgenic-rats/ (accessed 22 Dec 2015).
27. Chao CC, Chen SJ, Adamopoulos IE, et al. Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis. Autoimmunity 2011;44:243-52.
28. Adamopoulos IE, Chao CC, Geissler R, et al. Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors. Arthritis Res Ther 2010;12:R29.
29. Koenders MI, Lubberts E, Oppers-Walgreen B, et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol 2005;167:141-9.
30. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis-results of two phase three trials. N Engl J Med 2014;371:326-8.
31. Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med 2015;373:1329-3.
32. Baeten D, Sieper J, Braun J, et al, on behalf of the MEASURE 1 and MEASURE 2 Study Groups. Secukinumab interleukin-17A inhibition in ankylosing spondylitis. N Engl J Med 2015;373:2534-48.
33. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity ndex. J Rheumatol 1994;21:2286-91.
34. Ware JE, Kosinski M, Dewey JE How to score Version Two of the SF-36 Health Survey. Lincoln, RI: Quality Metric, 2000.
35. Doward LC, Spoorenberg A, Cook SA, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003;62:20-6.
36. Creemers MC, Franssen MJ, van't Hof MA, et al. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005;64:127-9.
37. Baraliakos X, Listing J, Rudwaleit M, et al. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis 2007;66:910-15.
38. Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 June 2010 (http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf).
39. Klein U, Liang E, Vogel B, et al. Immunogenicity of the novel anti-il-17a antibody, secukinumab, with intravenous and subcutaneous dosing regimens in healthy subjects and patients. Ann Rheum Dis 2013;72(Suppl 3):630.
40. Haroon N, Inman RD, Learch TJ, et al. The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 2013;65:2645-54.
41. Baraliakos X, Haibel H, Listing J, et al. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 2014;73:710-15.
42. Poddubnyy D, Haibel H, Listing J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 2012;64:1388-98.
43. Sieper J, Listing J, Poddubnyy D, et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis 2016;75:1438-43.
44. Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011;332:65-8.
45. Mathieu S, Gossec L, Dougados M, et al. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011;63:557-63.
46. Skroza N, Proietti I, Pampena R, et al. Correlations between psoriasis and inflammatory bowel diseases. Biomed Res Int 2013;2013:983902.
47. O'Connor W Jr, Kamanaka M, Booth CJ, et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol 2009;10:603-9.
48. Braun J, Baraliakos X, Listing J, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007;57:639-47.
49. van der Heijde D, Landewé R, van der Linden S. How should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measured? Arthritis Rheum 2005;52:1979-85.